On February 1, 2023 Cytokinetics, Incorporated (Nasdaq: CYTK) reported that on January 31, 2023 it granted stock options to purchase an aggregate of 87,600 shares of common stock to 13 new employees, whose employment commenced in January 2023, as a material inducement to their employment (Press release, Cytokinetics, FEB 1, 2023, View Source [SID1234626724]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The stock options that were granted are subject to an exercise price of $42.48 per share, which is equal to the closing price of the Company’s common stock on January 31, 2023, and will vest over 4 years, with 1/4th of the shares underlying the employee’s option vesting on the one-year anniversary of the applicable vesting commencement date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying each employee’s option over the subsequent 36 months, subject to the new employee’s continued service with the Company. Each stock option has a 10-year term and is subject to the terms and conditions of the Company’s Amended and Restated 2004 Equity Incentive Plan and the stock option agreement pursuant to which the option was granted.

The options were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

On February 1, 2023 Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, reported that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2023 Healthcare Talks Oncology Day taking place Feb. 8 – 9, 2023, at the St. Regis Hotel in New York City. Details are as follows (Press release, Candel Therapeutics, FEB 1, 2023, View Source [SID1234626723]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Format: Fireside Chat

Date/Time: Wednesday, February 8, 2023, at 3:20 p.m. EST

A live webcast of the session will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candel.com. A replay of the webcast will be archived for up to 30 days following the session date.

On February 1, 2023 Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, reported that the Company will be participating in the 2023 Guggenheim Oncology Conference taking place February 8-9, 2023 in New York City (Press release, Onconova Therapeutics, FEB 1, 2023, View Source [SID1234626722]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Steven Fruchtman, M.D., President & CEO of Onconova, will participate in a fireside chat on February 8, 2023, at 10:45 a.m. ET. A webcast of the fireside chat will be available here. Following the presentation, a replay will be archived on the "Corporate Events and Presentations" section of the Onconova website.

The Company will also be participating in 1×1 investor meetings at the conference on February 8 and 9, 2023. Meetings can be requested via Guggenheim.

On February 1, 2023 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, reported that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference, taking place virtually February 8-9, 2023 (Press release, Cue Biopharma, FEB 1, 2023, View Source [SID1234626721]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Suri will present an overview of Cue Biopharma’s Immuno-STAT (Selective Targeting and Alteration of T cells) platform and interleukin 2 (IL-2)-based CUE-100 series of biologics designed to enable selective targeting of IL-2 to tumor-specific T cells.

Presentation Details

Immuno-Oncology 360o
Presentation title: Development, Validation and Application of TCR-selective Engagers for In Vivo Modulation and Persistence of Cell Therapy Products in IO
Presenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma
Session: Track A: Novel Engineered Cell Therapies and Concepts
Date and time: February 7, 2023, 4:25 – 4:40 p.m. ET

FASEB Catalyst Conference
Presentation title: Immuno-STATs: TCR-selective Engagers of Tumor-specific T Cells
Presenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma
Date and time: February 9, 2023, 2:00 – 2:30 p.m. ET

On February 1, 2023 Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), reported that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences (Press release, Merus, FEB 1, 2023, View Source [SID1234626720]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Healthcare Talks/Oncology Conference: Wednesday, February 8 at 11:20-11:45 a.m. ET
SVB Securities Global Biopharma Conference: Tuesday, February 14 at 3:40-4:10 p.m. ET
Citi’s 2023 Oncology Leadership Summit: Thursday, February 23 at 10:00-11:00 a.m. ET
The webcasts of the presentations will be contemporaneously available on the Investors page of the Company’s website. Archived presentations will also be available there for a limited time after the event.